Drug Database
Back to search

Poland· PL-100309042

Cinryze

A c1-inhibitor, plasma derived product containing inhibitor c1 (ludzki), registered in Poland by Takeda Manufacturing Austria AG. The same ATC class is registered in 11 of our 19 countries.

ATC B06AC01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedCinryzeATCB06AC01REGISTER NO.PL-100309042PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about inhibitor c1 (ludzki)Answers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

C1-inhibitor, plasma derived is registered in 11 of 19 countries.

Countries holding a registration under ATC B06AC01 (c1-inhibitor, plasma derived), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search c1-inhibitor, plasma derived products by name

C1-inhibitor, plasma derived · ATC B06AC01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Inhibitor C1 (ludzki)
Manufacturer
Takeda Manufacturing Austria AG
Country
Poland (PL)
ATC code
B06AC01
ATC class
C1-inhibitor, plasma derived
Defined daily dose
1.4 TSD, E
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    07038319161504
  • gtin
    00642621072112

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

47 interactions on record for c1-inhibitor, plasma derived.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check c1-inhibitor, plasma derived against other medicinesHow interaction checks work

C1-inhibitor, plasma derived · interactions on record

47 records

  • 5 severe
  • 42 moderate

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

C1-inhibitor, plasma derived in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All c1-inhibitor, plasma derived products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Berinert
  • Belgium · Berinert
  • Bulgaria · Беринерт
  • Cyprus · Berinert
  • Czechia · Berinert
  • Germany · Berinert
  • Denmark · Berinert
  • Estonia · Berinert Iv, Berinert Sc
  • Spain · Berinert
  • Finland · Berinert
  • France · Berinert
  • United Kingdom (Northern Ireland) · Berinert
  • Greece · Berinert
  • Croatia · Berinert
  • Hungary · Berinert
  • Ireland · Berinert
  • Iceland · Berinert, Cinryze
  • Italy · Berinert
  • Liechtenstein · Cinryze
  • Lithuania · Human C1-Esterase Inhibitor Csl Behring
  • Luxembourg · Berinert
  • Malta · Berinert
  • Netherlands · Berinert
  • Norway · Berinert, Cinryze
  • Portugal · Berinert
  • Romania · Berinert
  • Sweden · Berinert
  • Slovenia · Berinert
  • Slovakia · Berinert

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b8045b47-c36b-4f12-8811-f42430e00f76
GET /v1/drugs/b8045b47-c36b-4f12-8811-f42430e00f76?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "500 jednostek",
  "packaging": "07038319161504 ¦ Rpz ¦ EU/1/11/688/001 ¦ 88465\n2 fiol.  proszku ¦ 2 fiol.  rozp. ¦ 2 urządzenie  do filtracji i transferu ¦ 2 zestawy  do nakłucia żyły + 2 maty ochronne ¦ 2 strzyk. 10 ml\n¦ UR/Z/4c/191/24 - 00642621072112",
  "substance": "Inhibitor C1 (ludzki) Inhibitor C1 humanum",
  "common_name": "Inhibitor C1 (ludzki)",
  "pl_product_id": "100309042",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about c1-inhibitor, plasma derived.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console